A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer.
about
A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
A phase IIa study of HA-irinot ...... -stage small cell lung cancer.
@en
A phase IIa study of HA-irinot ...... -stage small cell lung cancer.
@nl
type
label
A phase IIa study of HA-irinot ...... -stage small cell lung cancer.
@en
A phase IIa study of HA-irinot ...... -stage small cell lung cancer.
@nl
prefLabel
A phase IIa study of HA-irinot ...... -stage small cell lung cancer.
@en
A phase IIa study of HA-irinot ...... -stage small cell lung cancer.
@nl
P2093
P2860
P1476
A phase IIa study of HA-irinot ...... e-stage small cell lung cancer
@en
P2093
Beena Kumar
Ben Markman
D Neil Watkins
Ilia Banakh
Vinod Ganju
P2860
P2888
P304
P356
10.1007/S10637-017-0555-8
P577
2017-12-26T00:00:00Z